financetom
Business
financetom
/
Business
/
CME Group profit jumps on record trading strength
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CME Group profit jumps on record trading strength
Oct 23, 2024 4:36 AM

(Reuters) -CME Group ( CME ) reported a rise in third-quarter profit on Wednesday, as uncertainty around the U.S. monetary policy path led investors to rejig their portfolio, bolstering trading volumes for the derivatives exchange.

Trading volumes at exchanges tend to jump during periods of heightened uncertainty as clients increase hedging activity to manage risks.

This drove double-digit growth across all CME asset classes in the reported quarter.

The company's total average daily volume (ADV) jumped 27% from a year earlier to a quarterly record of 28.3 million contracts.

The ADV of interest rate products, which are often used to hedge against volatility stemming from changes in the benchmark interest rates, jumped 36% to a quarterly record of 14.9 million contracts.

Equities trading was another bright spot as volatility sparked by a sell-off in August, following a weaker-than-expected July jobs report, bolstered volumes. CME's equities ADV jumped 17% to 7.4 million contracts in the quarter.

"Q3 2024 was the best quarter in CME Group ( CME ) history," said CEO Terry Duffy.

Meanwhile, CME's energy ADV jumped 21% to 2.6 million contracts. Mounting geopolitical tensions in the Middle East have increased volatility in the global commodity and energy markets.

Clearing and transaction fees, CME's chief source of revenue, jumped 19.5% to $1.30 billion in the reported quarter, while market data revenue rose 6.3% to $178.2 million.

Total revenue jumped 18.4% to record $1.6 billion.

Net income attributable to common shareholders of CME Group ( CME ) rose to $901.3 million, or $2.50 per share, in the three months ended Sept. 30, from $740.8 million, or $2.06 per share, a year earlier.

CME shares have risen 7.4% so far this year, underperforming the 22.7% jump in the benchmark S&P 500 index.

(Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Shinjini Ganguli)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Canadian Pacific Kansas City, Americold Realty Trust to Explore Project Opportunities in Mexico
Canadian Pacific Kansas City, Americold Realty Trust to Explore Project Opportunities in Mexico
Dec 12, 2024
09:46 AM EST, 12/12/2024 (MT Newswires) -- Canadian Pacific Kansas City ( CP ) (CP, CP.TO) and Americold Realty Trust ( COLD ) said Thursday that they will formally explore co-development opportunities in Mexico under their collaboration to optimize temperature-sensitive logistics between the US, Mexico and Canada. The companies formed the collaboration last year and broke ground on their planned...
Esperion Therapeutics Signs Licensing Deal for Nexletol, Nexlizet in Israel
Esperion Therapeutics Signs Licensing Deal for Nexletol, Nexlizet in Israel
Dec 12, 2024
09:47 AM EST, 12/12/2024 (MT Newswires) -- Esperion Therapeutics ( ESPR ) said Thursday it has signed a licensing deal with Neopharm Israel for the exclusive rights to commercialize cholesterol medications Nexletol and Nexlizet in Israel. Under the terms of the agreement, Esperion will grant Neopharm exclusive commercialization rights to the drugs in Israel, Gaza, and the West Bank. In...
Archer Aviation, Anduril Industries Collaborate to Develop Hybrid VTOL Aircraft
Archer Aviation, Anduril Industries Collaborate to Develop Hybrid VTOL Aircraft
Dec 12, 2024
09:46 AM EST, 12/12/2024 (MT Newswires) -- Archer Aviation ( ACHR ) said Thursday it is collaborating with Anduril Industries to co-develop a hybrid verticle take-off and landing aircraft for defense applications, for a potential US Department of Defense initiative. Financial details weren't disclosed. To advance this initiative Archer raised $430 million in equity funding from Stellantis ( STLA )...
Aptevo Therapeutics Shares Rally After Trial Results Show Complete Remission by Acute Myeloid Leukemia Patients
Aptevo Therapeutics Shares Rally After Trial Results Show Complete Remission by Acute Myeloid Leukemia Patients
Dec 12, 2024
09:49 AM EST, 12/12/2024 (MT Newswires) -- Aptevo Therapeutics ( APVO ) shares were surging early Thursday after the company said all of the patients with acute myeloid leukemia treated with its mipletamig bispecific antibody achieved remission within 30 days of treatment in a phase 1b trial, including two patients in the cohort who experienced complete remission with 100% elimination...
Copyright 2023-2026 - www.financetom.com All Rights Reserved